BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20463350)

  • 1. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
    Feelders RA; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; van Heerebeek R; de Jong FH; van der Lely AJ; de Herder WW; Hofland LJ; Lamberts SW
    N Engl J Med; 2010 May; 362(19):1846-8. PubMed ID: 20463350
    [No Abstract]   [Full Text] [Related]  

  • 2. Case Report: Opposite Tumoral and Hormonal Responses to Low-dose Pasireotide in Cushing's Disease.
    Serban AL; Zampetti B; Saladino A; Favero V; Chiodini I; Cozzi R
    Endocr Metab Immune Disord Drug Targets; 2024; 24(7):845-849. PubMed ID: 37937561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future treatment strategies of aggressive pituitary tumors.
    Lamberts SW; Hofland LJ
    Pituitary; 2009; 12(3):261-4. PubMed ID: 19003539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giant leaps forward.
    Trainer P
    Clin Med (Lond); 2009 Aug; 9(4):363-4. PubMed ID: 19728514
    [No Abstract]   [Full Text] [Related]  

  • 5. A 12-month phase 3 study of pasireotide in Cushing's disease.
    Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
    N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
    Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
    Pivonello R; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Trovato A; Hughes G; Salgado LR; Lacroix A; Schopohl J; Biller BM;
    Clin Endocrinol (Oxf); 2014 Sep; 81(3):408-17. PubMed ID: 24533697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Treatment of Cushing's Disease.
    Pivonello R; De Leo M; Cozzolino A; Colao A
    Endocr Rev; 2015 Aug; 36(4):385-486. PubMed ID: 26067718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabergoline for Cushing's disease: a large retrospective multicenter study.
    Ferriere A; Cortet C; Chanson P; Delemer B; Caron P; Chabre O; Reznik Y; Bertherat J; Rohmer V; Briet C; Raingeard I; Castinetti F; Beckers A; Vroonen L; Maiter D; Cephise-Velayoudom FL; Nunes ML; Haissaguerre M; Tabarin A
    Eur J Endocrinol; 2017 Mar; 176(3):305-314. PubMed ID: 28007845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the medical treatment of Cushing's syndrome.
    Feelders RA; Newell-Price J; Pivonello R; Nieman LK; Hofland LJ; Lacroix A
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):300-312. PubMed ID: 30033041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
    Fleseriu M; Petersenn S; Biller BMK; Kadioglu P; De Block C; T'Sjoen G; Vantyghem MC; Tauchmanova L; Wojna J; Roughton M; Lacroix A; Newell-Price J
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):776-785. PubMed ID: 31465533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?
    Barbot M; Albiger N; Ceccato F; Zilio M; Frigo AC; Denaro L; Mantero F; Scaroni C
    Pituitary; 2014 Apr; 17(2):109-17. PubMed ID: 23468128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study.
    Lacroix A; Gu F; Schopohl J; Kandra A; Pedroncelli AM; Jin L; Pivonello R
    Pituitary; 2020 Jun; 23(3):203-211. PubMed ID: 31875276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence.
    Petersenn S; Beckers A; Ferone D; van der Lely A; Bollerslev J; Boscaro M; Brue T; Bruzzi P; Casanueva FF; Chanson P; Colao A; Reincke M; Stalla G; Tsagarakis S
    Eur J Endocrinol; 2015 Jun; 172(6):R227-39. PubMed ID: 25599709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Cushing's disease: a mechanistic update.
    Cuevas-Ramos D; Fleseriu M
    J Endocrinol; 2014 Nov; 223(2):R19-39. PubMed ID: 25134660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome.
    Valassi E; Crespo I; Gich I; Rodríguez J; Webb SM
    Clin Endocrinol (Oxf); 2012 Nov; 77(5):735-42. PubMed ID: 22533782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
    Fleseriu M; Biller BM; Findling JW; Molitch ME; Schteingart DE; Gross C;
    J Clin Endocrinol Metab; 2012 Jun; 97(6):2039-49. PubMed ID: 22466348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
    Lacroix A; Gu F; Gallardo W; Pivonello R; Yu Y; Witek P; Boscaro M; Salvatori R; Yamada M; Tauchmanova L; Roughton M; Ravichandran S; Petersenn S; Biller BMK; Newell-Price J;
    Lancet Diabetes Endocrinol; 2018 Jan; 6(1):17-26. PubMed ID: 29032078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.
    Boscaro M; Bertherat J; Findling J; Fleseriu M; Atkinson AB; Petersenn S; Schopohl J; Snyder P; Hughes G; Trovato A; Hu K; Maldonado M; Biller BM
    Pituitary; 2014 Aug; 17(4):320-6. PubMed ID: 23943009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study.
    Manetti L; Deutschbein T; Schopohl J; Yuen KCJ; Roughton M; Kriemler-Krahn U; Tauchmanova L; Maamari R; Giordano C
    Pituitary; 2019 Oct; 22(5):542-551. PubMed ID: 31440946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.